Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Business Wire
New predictive data evaluates patient outcomes up to 24.8 months post-surgery, confirms findings presented at ASCO GI 2022 AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which demonstrates the ability of the SignateraTM molecular residual disease (MRD) test to identify patients with stage II-IV colorectal cancer (CRC) who are at an increased risk of recurrence and predict who is likely to benefit from adjuvant chemotherapy (ACT). With this study, data supporting the clinical validity and utility of Signatera has now been published in 40 peer-reviewed publications.The paper describes results from the GALAXY arm of the ongoing CIRCULATE-Japan trial, which is one of the largest and most comprehensive prospective studies of MRD testing in resectable CRC. The data builds on results previously presented at the 2022 ASCO Gastrointestinal Cancers Symposium (ASCO GI), n
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera (NTRA) Rose on Momentum in the Oncology Market [Yahoo! Finance]Yahoo! Finance
- Natera, Inc. (NASDAQ: NTRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications [Yahoo! Finance]Yahoo! Finance
- Natera Announces Significant Milestone with 200+ Peer-Reviewed PublicationsBusiness Wire
- Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $90.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
NTRA
Earnings
- 2/28/24 - Beat
NTRA
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEF
- 4/24/24 - Form DEFA14A
- NTRA's page on the SEC website